bullish

APAC Healthcare Weekly (April 6)- Nippon Shinyaku, Shionogi, Beigene, Celltrion, Mesoblast, Lupin

599 Views06 Apr 2025 08:30
Nippon Shinyaku and Shionogi are filing for new drugs. Beigene dropped a phase 3 oncology asset. Mesoblast is about to start treatment with Ryoncil. Lupin is acquiring UK-based Renascience Pharma.
What is covered in the Full Insight:
  • Nippon Shinyaku NDA Submission
  • Shionogi FDA Rolling NDA for Xocova
  • BeiGene Ociperlimab Update
  • Celltrion CHMP Opinion for Omlyclo
  • Pharmaceutical Sector and Tariffs Impact
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
x